Navigation Links
ArunA Biomedical Awarded Department of Defense Contract to Further Develop Environmental Biosensor for National Security
Date:3/31/2009

ATHENS, Ga., March 31 /PRNewswire/ -- ArunA Biomedical, Inc., a leader in human embryonic stem cell derived products, announced today that it has been awarded a Department of Defense contract to develop an environmental biosensor utilizing its human stem cell technology.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080819/CLTU003LOGO)

The company will further develop a human embryonic stem cell derived cellular model for use in a prototype biosensor developed by the Naval Research Laboratory and previously studied by the University of Georgia. Current cell sources have a limited lifespan in the field requiring frequent replacement thereby reducing the efficiency and accuracy of testing environmental toxins. ArunA is well positioned to enhance the Naval Research Laboratory's work in this area by offering a robust consistent population of human cells and expanding the capability of sensor technology.

"Effective monitoring and regulation of environmental contamination remains a major challenge of great importance for both military and civilian populations," commented David Ray, ArunA CEO. "ArunA is pleased to have an opportunity to further develop a technology that could aide national security and field combat."

About ArunA Biomedical

Located in Athens, Georgia, ArunA Biomedical, Inc. is a privately held biotechnology corporation dedicated to the discovery, manufacturing and commercialization of emerging new technologies in human stem cell research for use in drug discovery and basic research. ArunA is the first company to commercialize products derived from human embryonic stem cells and sees its proprietary technology as a catalyst leading to the discovery of novel therapeutic compounds, tests for neurotoxicity and breakthroughs in understanding human development and diseases. For more information, visit: www.arunabiomedical.com

This press release contains forward-looking statements regarding the company's potential impact on scientific research and collaborations with third parties. Certain conditions could alter the outcome or progress of these statements including but not limited to unexpected manufacturing issues, product performance and quality control/assurance issues. Forward-looking statements are based on the opinions, beliefs and expectations of the company or individuals quoted in the press release and the company does not assume any obligation to update these forward-looking statements if circumstances change.


'/>"/>
SOURCE ArunA Biomedical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ArunA Biomedical Announces Co-development of Fully Validated Induced Pluripotent Stem Cell Kit
2. ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Mesenchymal Cells
3. ArunA Biomedical, Inc. Announces Alliance with Neuromics for Distribution of Normal Human Neural Cells
4. ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Neural Cells
5. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
6. ArunA Biomedical Names William T. Sharp President and Chief Executive Officer
7. BioMedical Enterprises, Inc. (BME) Announces the Appointment of Keith M. Peeples as Vice President, Sales and Marketing
8. Collexis Connects Biomedical Researchers and Clinical Scientists with the Collexis Expert Platform for Translational Research
9. The NIHR Biomedical Research Centre for Mental Health London has Joined the MetaMiner CNS Partnership Program
10. PAREXEL Expert to Address Value of Incorporating Asia Into Global Clinical Development at BioMedical Asia 2009
11. Environmental Tectonics Corporations BioMedical Divisions Hyperbaric Chambers Address U.S. President Obamas Initiative to Computerize Medical Records
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... 2017 , ... NLP Logix today announced a collaboration to ... Mayo Clinic and the experience in developing and deploying artificial intelligence solutions by ... Azure platform and will focus on assisting physicians to more accurately and efficiently ...
(Date:7/25/2017)... ... July 25, 2017 , ... Fiberstar, Inc ., a ... industry, offers Citri-Fi® 125. This natural citrus fiber is used to improve tomato-based food ... tomato in sauces, condiments and spreads. Today, more than ever, consumers connect ingredients to ...
(Date:7/24/2017)... , July 24, 2017 Intralytix, Inc. announced ... from Lesaffre, a French family group. This investment marks ... to develop and commercialize bacteriophage-based products, for various benefits ... interest. As ... designs manufactures and markets innovative solutions for baking, food ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... leading radiology and imaging centers around the U.S. that offer MR Elastography for ... alternative to needle biopsy for staging liver fibrosis assessment. , “MRE:connect was ...
Breaking Biology Technology:
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:3/30/2017)... -- The research team of The Hong Kong Polytechnic ... by adopting ground breaking 3D fingerprint minutiae recovery and matching technology, ... accuracy for use in identification, crime investigation, immigration control, security of ... ... A research team led by Dr ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
Breaking Biology News(10 mins):